<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">
  <url>
    <loc>https://aktiv8.io/news/nczlmx1/merck-says-phase-3-trofuse-015-trial-of-sac-tmt-met-its-survival-endpoint-in-gastroesophag</loc>
    <lastmod>2026-11-21</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1ukfsu6/regeneron-gained-fda-approval-for-rnai-treatment-livsayis-labroots</loc>
    <lastmod>2026-11-21</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nvi25no/dual-antiviral-regimen-suppresses-chronic-hepatitis-delta-in-phase-3-emj</loc>
    <lastmod>2026-11-21</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1jhgda5/capricor-therapeutics-provides-regulatory-update-on-deramiocel-bla-for-duchenne-muscular-d</loc>
    <lastmod>2026-11-21</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nuuvjsy/fda-again-turns-back-capricor-duchenne-cell-therapy</loc>
    <lastmod>2026-11-21</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nfr5p27/fda-rejects-capricor-s-duchenne-cell-therapy-deramiocel-citing-data-integrity-violations-i</loc>
    <lastmod>2026-11-21</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/na6yub2/rxerp-outlines-what-the-fda-s-move-to-12-digit-ndcs-means-for-pharma-product-data</loc>
    <lastmod>2026-11-21</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1d7j43u/nektar-therapeutics-targets-december-for-phase-3-alopecia-trial-as-rezpeg-advances-newsbre</loc>
    <lastmod>2026-11-21</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nih2sz6/epitech-horus-pharma-sign-global-adelmidrol-licensing-deal-for-eye-health-contract-pharma</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n12bxx5b/erasca-data-add-to-pressure-facing-revolution-s-breakthrough-cancer-drug-biopharma-dive</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nytreqn/caliway-s-cbl-514-receives-early-ind-clearance-in-china-accelerating-development-in-the-wo</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nqfomq1/biotech-collaborations-market-outlook-report-including-segment-analysis-and-strategic-indu</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nn7t83/sanofi-gets-genzyme-asset-across-fda-finish-line-with-key-nod-in-gaucher-type-3-fierce-pha</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nvryff8/merck-s-trop2-adc-extends-survival-in-pivotal-gastroesophageal-cancer-trial</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1mmmyic/stat-fda-rejects-capricor-therapeutics-duchenne-therapy-a-decision-that-was-a-long-time-co</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nu6pwjf/annovis-secures-fda-agreement-on-integrated-summary-of-safety-plan-combining-alzheimer-s-a</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nhsvbnw/subaru-names-make-a-wish-a-subaru-share-the-love-event-national-charity-partner-for-16th-c</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ndwx7fq/bausch-lomb-and-celldex-rocked-by-respective-phase-2-flops</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ngpj7k2/celldex-drops-atopic-dermatitis-study-following-weak-phase-2-pruritus-data-benzinga</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nfnsxdw/pmv-pharmaceuticals-announces-promising-updated-data-from-the-pynnacle-phase-2-pivotal-tri</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nqpdasr/merck-s-trop2-adc-extends-survival-in-pivotal-gastroesophageal-cancer-trial</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ni0bf8/merck-announces-trofuse-015-trial-evaluating-sacituzumab-tirumotecan-sac-tmt-met-primary-e</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n108tn0p/bioversys-gsk-partnered-antibiotic-combo-shows-promise-in-phase-ii-tb-trial</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nq4oo8n/merck-s-sacituzumab-tirumotecan-improves-survival-in-advanced-gastroesophageal-cancer-in-p</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n2l22te/belite-bio-announces-extension-of-fda-review-timeline-for-tinlarebant-nda</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1rz8be0/a-pill-to-slow-alzheimer-s-progression-korean-drug-shows-some-promise-in-phase-3-trial-kor</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nv1gqh0/erasca-reports-broad-and-robust-phase-1-clinical-efficacy-and-favorable-safety-data-for-pa</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nopnrtm/merck-gets-another-phase-3-win-for-sac-tmt-this-time-in-gastric-cancer</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n12rwuw1/cel-sci-s-multikine-receives-saudi-fda-nadr-designation-accelerating-potential-commercial-</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1o8wa58/bausch-lomb-and-celldex-rocked-by-respective-phase-2-flops</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1fg55cf/it-s-a-very-healthy-sector-biopharma-gathers-in-london-as-m-a-shines-and-china-clouds-loom</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nnadob5/fda-approves-sanofi-pill-as-first-treatment-for-brain-effects-of-rare-gaucher-disease-medw</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ncikzje/gehc-advances-manganese-based-mri-agent-to-phase-3-after-positive-data-the-globe-and-mail</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nn96v82/epitech-group-and-horus-pharma-sign-global-licensing-agreement-for-adelmidrol-in-ophthalmo</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n13h1af0/novo-s-sogroya-receives-fda-approval-as-the-first-and-only-once-weekly-long-acting-growth-</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1gnfr5y/aprea-therapeutics-announces-interim-results-from-the-ongoing-first-in-human-phase-1-study</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/na77f4b/aribio-charts-new-path-for-korean-biotech-with-global-phase-3-alzheimer-s-trial-korea-biom</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nv0paze/merck-phase-3-trial-shows-survival-benefit-in-advanced-cancer-grafa-com</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1ppgcmc/new-fda-neuroscience-initiative-offers-opportunity-to-biotech-firms-law-com</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1g816yu/caliway-s-cbl-514-receives-early-ind-clearance-in-china-accelerating-development-in-the-wo</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1vgazk7/mixed-topline-phase-3-results-for-pde5-inhibitor-in-early-ad-medscape</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1jjjl9e/daraxonrasib-shrinks-pancreatic-cancer-tumours-in-phase-3-rasolute-302-trial-casrai</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ndgw8xi/merck-mrk-reports-positive-phase-3-trial-results-for-sacituzum-gurufocus</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nrw5zil/epitech-group-and-horus-pharma-sign-a-global-licensing-agreement-to-develop-adelmidrol-in-</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n16gjlwb/avenzo-therapeutics-merger-launches-a-nasdaq-listed-oncology-biotech-with-215m-in-new-capi</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ntzhsj9/erasca-reports-broad-and-robust-phase-1-clinical-efficacy-and-favorable-safety-data-for-pa</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1u26byt/novo-s-sogroya-receives-fda-approval-as-the-first-and-only-once-weekly-long-acting-growth-</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1sz47k7/merck-co-stock-phase-3-drug-trial-meets-survival-goal-ad-hoc-news-de</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1uol0dw/pmv-pharma-reports-48-orr-and-durable-responses-for-rezatapopt-in-platinum-resistant-ovari</loc>
    <lastmod>2026-11-20</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n6x1w15/cg-oncology-reports-positive-topline-results-in-large-phase-3-trial-for-ir-nmibc-traders-u</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/njulh5t/interlude-biopharma-launches-at-the-international-celiac-disease-symposium-and-announces-p</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1vr6mjt/in-hellonation-wellness-expert-and-bodybuilding-com-ceo-andres-giraldo-addresses-fda-appro</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n3dt5yx/enable-injections-and-arespo-biopharma-announce-strategic-partnership-carroll-county-mirro</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n16kth72/fda-nod-for-regeneron-s-livsayis-in-gmg-the-pharma-letter</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nu3p6lb/neonc-technologies-announces-fda-rescheduled-neo212-end-of-phase-1-type-b-meeting-to-novem</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1ljo2d5/opus-genetics-announces-first-participant-dosed-in-phase-1-2-clinical-trial-of-opgx-rdh12-</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nba7td2/betta-pharmaceuticals-and-mankind-pharma-reach-exclusive-licensing-agreement-for-ensartini</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n49apqh/hutchmed-highlights-hmpl-a830-pre-clinical-data-presented-at-the-38th-eortc-nci-aacr-inter</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nj0offp/alnylam-collaborator-regeneron-secures-fda-approval-of-livsayis-cemdisiran-the-seventh-fda</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nkp5qo3/after-four-biotech-owners-and-a-major-trial-failure-beren-s-rare-pediatric-disease-drug-fi</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1aexq4g/evotec-and-bristol-myers-squibb-advance-strategic-protein-degradation-partnership-with-sec</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1cwob36/adcendo-aps-announces-phase-1-clinical-data-showing-compelling-safety-antitumor-activity-w</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nxdpwk3/opus-genetics-announces-first-participant-dosed-in-phase-1-2-clinical-trial-of-opgx-rdh12-</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1fpngbx/new-fda-approved-pill-lowers-high-blood-pressure-and-may-slow-kidney-disease-scitechdaily</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1rny59v/crfb-investigation-baby-food-above-fda-lead-level-sold-at-harris-teeter-despite-new-state-</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1hudz25/bellwave-program-for-nemtabrutinib-discontinued-after-phase-3-cll-sll-trial-cancernetwork</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ngts6n6/johnson-johnson-seeks-u-s-fda-approval-for-caplyta-in-bipolar-mania-marking-fifth-potentia</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1s1fmtb/ge-healthcare-s-phase-2-results-support-advancement-of-investigational-manganese-based-mri</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nkv0s25/ge-healthcare-s-phase-2-results-support-advancement-of-investigational-manganese-based-mri</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nvm7jbk/vidac-pharma-will-now-focus-activity-on-seeking-partnering-for-a-phase-3</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1yi8esc/celldex-reports-results-from-phase-2-study-of-barzolvolimab-in-atopic-dermatitis</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n58q0dm/adcendo-aps-announces-phase-1-clinical-data-showing-compelling-safety-antitumor-activity-w</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n2i2xcl/humacyte-submits-supplemental-biologics-license-application-to-fda-for-the-acellular-tissu</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1xlru5r/vidac-pharma-will-now-focus-activity-on-seeking-partnering-for-a-phase-3-ein-news</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1xxepwm/stat-merck-isomorphic-labs-partner-to-develop-oncology-drug-candidates</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1n1hqi2/adcendo-aps-announces-phase-1-clinical-data-showing-compelling-safety-antitumor-activity-w</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/njgphsy/regeneron-wins-fda-approval-for-first-sirna-treatment-for-myasthenia-gravis</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n5gjt2z/revolution-medicines-presents-updated-phase-1-2-data-for-rasonque-quantisnow</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1o5m2x8/innovative-health-receives-fda-clearance-to-reprocess-octaray-mapping-catheter</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nn76vwq/india-and-italy-seek-stronger-collaboration-in-pharma-and-technology-asianet-newsable</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1kpfw22/ge-healthcare-s-phase-2-results-support-advancement-of-investigational-manganese-based-mri</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n140r5yu/candel-therapeutics-cadl-faces-investor-scrutiny-after-surprise-bla-delay-drives-stock-26-</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nn5meg8/enable-injections-and-arespo-biopharma-establish-strategic-partnership-to-advance-biopharm</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1sf7bik/adcendo-aps-announces-phase-1-clinical-data-showing-compelling-safety-antitumor-activity-w</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n7nodim/burl-concepts-announces-fda-510-k-clearance-for-foqus-ultrasound-system-for-rapid-automate</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1sfbkfn/dt-120-in-anxiety-and-depression-phase-3-efficacy-and-safety-findings-psychiatric-times</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n15a4t0z/revolution-medicines-reports-encouraging-updated-phase-1-2-data-for-rasonque-plus-gemcitab</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1vyr3ba/tvardi-therapeutics-advances-next-generation-oral-stat3-inhibitor-tti-109-toward-ind-in-in</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1hboqw/pubmatic-named-primary-international-partner-for-nippon-tv-s-sugree-platform-opening-japan</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1bh8s5z/mile-high-labs-files-type-ii-drug-master-file-with-fda-for-cbd-isolate</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1qaxsvs/medivir-scores-us-regulatory-breakthrough-for-bone-disease-drug-www-lifesciencefocus-com</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nsmnozb/arcera-strikes-1b-pact-to-license-innogen-s-approved-glp-1-outside-china-fierce-pharma</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1kz3953/with-fda-nod-regeneron-brings-an-rnai-drug-to-autoimmune-disease</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nq9uk1v/ge-healthcare-technologies-inc-ge-healthcare-s-phase-2-results-support-advancement-of-inve</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1npuf4b/sonic-incytes-madrigal-ink-multi-year-partnership-for-mash-therapeutics-contract-pharma</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nbp2nf5/fda-approval-for-livsayis-issued-to-regeneron-pharmaceuticals-quantisnow</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nw5ps68/interlude-biopharma-launches-at-the-international-celiac-disease-symposium-and-announces-p</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nljsgt3/pfe-inks-2-6b-licensing-deal-with-chinese-biotech-for-car-t-therapies-tradingview</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nrsoyfd/actinogen-pivotal-alzheimer-s-disease-trial-demonstrates-clinical-benefit-in-older-patient</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1604d61/ge-healthcare-announces-phase-2-results-met-primary-endpoint-support-phase-3</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ndj6wxf/ge-healthcare-s-phase-2-results-support-advancement-of-investigational-manganese-based-mri</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1j7fmdt/fda-clears-ind-for-oculis-privosegtor-program-expansion-glance-by-eyes-on-eyecare</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nbyuahf/sonesitatug-vedotin-granted-priority-review-in-the-us-for-2nd-and-later-line-treatment-of-</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nwe7b4/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-601-in-phase-2-apollo-s</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1joqqza/massmutual-named-title-partner-of-2027-san-francisco-sail-grand-prix-tickets-on-sale-to-ge</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n5dqquz/sanofi-gains-fda-clearance-for-gaucher-disease-pill</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n7qdgvh/scancell-ceo-on-fda-breakthrough-melanoma-survival-data-and-phase-3-plans-proactive-financ</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1kggz5u/definium-reports-positive-phase-3-dt-120-results-wisevoter</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/noafng2/oclc-and-ecole-solutions-partner-to-bring-ezproxy-services-to-libraries-across-india</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1jocven/burl-concepts-announces-fda-510-k-clearance-for-foqus-ultrasound-system-for-rapid-automate</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1tja3ae/lupus-research-alliance-and-clinical-affiliate-lupus-therapeutics-form-new-collaboration-w</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ni5jekv/act-brief-trial-matching-nudges-federal-pressures-on-biotech-and-fda-leadership-vacancy-ap</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/njgwyp8/regeneron-pharmaceuticals-regn-fda-approvals-pdufa-dates-drug-alerts-2026-marketbeat</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1w4ud7/aribio-s-ar1001-meets-alzheimer-s-phase-3-goal-in-monotherapy-subgroup-but-not-overall-cas</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n19dsfyx/harbour-biomed-announces-nmpa-acceptance-of-ind-application-for-its-first-ai-enabled-drug-</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/npne12a/adagene-announces-first-patient-dosed-in-phase-1-study-of-adg138-a-novel-her2xcd3-double-m</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n18x730d/evotec-and-bristol-myers-squibb-advance-strategic-protein-degradation-partnership-with-sec</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1j4s0iu/revolution-medicines-presents-updated-phase-1-2-data-for-rasonque-daraxonrasib-plus-chemot</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ngr6bku/solenis-and-vertiv-partner-to-advance-liquid-cooling-management-for-ai-data-centers</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1ygxbgw/experimental-aml-vaccine-linked-to-nine-month-median-survival-gain-in-company-reported-pha</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1qznufo/congress-panel-warns-on-china-biotech-licensing-deals-wisevoter</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nl7tkef/remix-therapeutics-announces-updated-positive-rem-422-phase-1-data-in-adenoid-cystic-carci</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n6jkvmm/with-fda-nod-regeneron-brings-an-rnai-drug-to-autoimmune-disease-biopharma-dive</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1nb51yx/clinical-data-from-phase-3-adept-studies-evaluating-karxt-for-alzheimer-disease-psychosis-</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nlqqh0b/celldex-reports-results-from-phase-2-study-of-barzolvolimab-in-atopic-dermatitis-cldx-stoc</loc>
    <lastmod>2026-11-19</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ncng49x/pyxis-oncology-to-host-live-webcast-on-updated-micvo-phase-1-monotherapy-data-demonstratin</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nxxeldv/bristol-myers-squibb-bmy-reports-positive-phase-3-alzheimer-s-trial-results-supporting-div</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nzh11vr/verismo-therapeutics-licenses-in-vivo-car-t-engineering-technology-to-extend-its-novel-mul</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1368ez9/anixa-biosciences-and-curia-will-develop-final-formulation-for-breast-cancer-vaccine-in-pr</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nwfnyn3/ichnos-glenmark-innovation-igi-gibt-die-einreichung-eines-ind-antrags-bei-der-us-amerikani</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nabxhx3/merck-discontinues-nemtabrutinib-development-for-hematologic-malignancies-after-phase-3-be</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nniwi6e/racura-oncology-receives-first-site-approval-for-seamless-phase-2b-3-emili-trial-of-rc220-</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nl0ls3z/whoop-and-formula-1-partner-to-reveal-the-human-performance-behind-the-wheel</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n7phd3r/racura-oncology-receives-first-site-approval-for-seamless-phase-2b-3-emili-trial-of-rc220-</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nz1tchj/stat-fda-discloses-reasons-for-rejecting-summit-drug</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n108d8c8/optimi-health-updates-psychedelic-clinical-pipeline-with-amended-opti-101-phase-2b-planned</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nlpzztz/innate-pharma-presents-initial-phase-1-clinical-data-for-iph4502-at-ena-2026</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1fqwzrp/nervgen-appoints-sam-jackson-as-chief-medical-officer-to-lead-phase-3-restore-study-of-nvg</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nhcjx0g/masimo-receives-fda-510-k-clearance-for-smartsedline-to-advance-brain-health-during-anesth</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nck3ewe/dignify-therapeutics-doses-first-healthy-participant-in-phase-1-study-of-dti-117-for-neuro</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1rsvgze/telomir-pharmaceuticals-selects-linical-to-advance-fda-cleared-phase-1-2-clinical-trial-of</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1fgfg8o/harbour-biomed-announces-nmpa-acceptance-of-ind-application-for-its-first-ai-enabled-drug-</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nvdtmt3/recursion-announces-alignment-with-fda-on-registrational-phase-3-quantisnow</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1lwrlj/verismo-therapeutics-licenses-in-vivo-car-t-engineering-technology-to-extend-its-novel-mul</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n16dtjzp/novel-direct-to-brain-intracerebroventricular-stem-cell-phase-1-trial-shows-safety-and-exc</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1s2w9vk/noetik-collaborates-with-leading-global-cancer-center-to-advance-the-next-generation-of-ca</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n6y9qrv/anixa-biosciences-and-curia-will-develop-final-formulation-for-breast-cancer-vaccine-in-pr</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1u3bqzf/igc-pharma-completes-dosing-in-phase-2-calma-trial-of-igc-ad1-for-agitation-in-alzheimer-s</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nyr7m2g/bristol-myers-squibb-presents-first-clinical-data-from-two-phase-3-studies-in-the-adept-pr</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nh8yj2n/igc-pharma-completes-dosing-in-phase-2-calma-trial-of-igc-ad1-for-agitation-in-alzheimer-s</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/neharhe/anixa-biosciences-and-curia-will-develop-final-formulation-for-breast-cancer-vaccine-in-pr</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1wqa05l/lynch-regenerative-medicine-lrm-announces-fda-authorization-of-two-new-inds-for-investigat</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nj0763d/stat-white-house-pulls-nomination-of-heidi-overton-to-lead-fda</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n6fc840/genomics-ltd-announces-extension-of-strategic-drug-discovery-collaboration-with-vertex-pha</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1fk45q4/fda-discloses-reasons-for-rejecting-summit-drug</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1ecf29b/innate-pharma-presents-initial-phase-1-clinical-data-for-iph4502-at-ena-2026-ipha-stock-ne</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n79ukzy/recursion-announces-fda-alignment-on-phase-3-trial-design-for-rec-4881-in-familial-adenoma</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n8p7sak/recursion-announces-alignment-with-fda-on-registrational-phase-3-trial-design-for-rec-4881</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n17roumy/hareholder-alert-the-m-a-class-action-firm-announces-an-investigation-of-aytu-biopharma-in</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1a9v6u6/faye-achieves-select-partner-tier-in-anthropic-s-claude-partner-network</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nvnydc7/pfizer-enters-in-vivo-car-t-space-via-3-program-2-6b-deal-with-china-s-starna</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/naasjdv/galinpepimut-s-improves-overall-survival-in-phase-3-aml-maintenance-trial-cancernetwork</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1koq32l/cognito-phase-3-flops-in-light-and-sound-alzheimer-s-trial-but-sees-signal-for-hope</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n8zmor0/samjin-pharm-calls-aribio-s-alzheimer-s-phase-3-trial-a-success-despite-mixed-results-kore</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n3o92kz/fziomed-announces-fda-510-k-clearance-for-dynavisc-tendon-protector-in-the-united-states</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nrzzufy/ichnos-glenmark-innovation-igi-annonce-le-depot-d-une-ind-aupres-de-la-fda-americaine-pour</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n9ddvo7/uniquity-bio-advances-esophageal-drug-toward-phase-3-trial-mychesco</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1kgynz1/ichnos-glenmark-innovation-igi-annonce-le-depot-d-une-ind-aupres-de-la-fda-americaine-pour</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n199rsn6/bristol-myers-squibb-presents-first-clinical-data-from-two-phase-3-studies-in-the-adept-pr</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n5vwg82/pfizer-licenses-car-t-therapies-from-china-s-starna-in-up-to-2-6-billion-deal</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nhrc5f0/pfizer-enters-in-vivo-car-t-space-via-3-program-2-6b-deal-with-china-s-starna</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n10jftpv/biostream-receives-fda-breakthrough-device-designation-for-a-urine-test-to-aid-the-diagnos</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n178svbt/innate-pharma-reports-iph4502-phase-1-cancer-trial-results-grafa-com</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n7xvbo4/senores-pharma-s-latest-regulatory-milestone-pic-s-gmp-certification-for-gujarat-facility-</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n6sx134/correction-neola-medical-q3-report-2026-fda-breakthrough-device-designation-strengthens-u-</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1yg9iml/experimental-bladder-cancer-drug-reduced-recurrence-risk-68-in-phase-3-trial-company-repor</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n9mbrv7/phase-3-results-for-xtoro-finafloxacin-otic-suspension-0-3-in-acute-otitis-externa-publish</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n75bya2/priavoid-s-alzheimer-s-pill-fails-to-prove-efficacy-in-phase-2-trial</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n4ueexe/immuneering-presents-additional-data-demonstrating-atebimetinib-s-broad-potential-as-a-bac</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n3z5jni/maia-and-karen-zupko-and-associates-inc-partner-to-bring-independent-coding-expertise-to-a</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nemo9fo/can-fite-pivotal-phase-iii-psoriasis-study-under-an-fda-and-ema-agreed-protocol-all-patien</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n18c8rd7/fda-drug-approval-decisions-expected-in-december-2026-mpr-medical-professionals-reference</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1allvhm/merck-axes-2-7b-btk-inhibitor-program-after-seeing-phase-3-data</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n87khnh/fda-publishes-rejection-letter-for-summit-drug-nuvalent-buyout-pays-more-dividends-for-gsk</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1bl0rmb/ichnos-glenmark-innovation-igi-gibt-die-einreichung-eines-ind-antrags-bei-der-us-amerikani</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nrt27mo/summit-s-rejection-letter-reveals-fda-s-deeper-concerns-about-trial-design-safety-biospace</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1xx0p7p/masimo-receives-fda-510-k-clearance-for-smartsedline-to-advance-brain-health-during-anesth</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n10jgght/lynch-regenerative-medicine-lrm-announces-fda-authorization-of-two-new-inds-for-investigat</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nr5b1yg/innate-pharma-ipha-reports-promising-phase-1-results-for-iph45-gurufocus</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1fs4krn/pfizer-licenses-in-vivo-car-t-therapies-from-starna-therapeutics-in-2-6b-deal-genomeweb</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1vml15d/stat-pharmalittle-we-re-reading-about-overton-fda-nomination-being-yanked-a-merck-setback-</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ngppqp1/mindmatrix-introduces-partner-mind-within-gtmos-unifying-partner-intelligence-sources-in-a</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1ukcsda/new-treatment-strategy-for-down-syndrome-shows-promise-in-phase-2-clinical-trial</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nhw1c6h/xdi-and-sumclimate-partner-to-strengthen-climate-risk-analysis-and-reporting</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nhmrev3/new-treatment-strategy-for-down-syndrome-shows-promise-in-phase-2-clinical-trial</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n10nns2w/clene-nanomedicine-uses-cro-veristat-s-biostatistics-platform-for-fda-submission</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1yxv356/corbus-pharmaceuticals-starts-phase-3-cancer-study-weighs-next-steps-for-obesity-drug-trad</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n13fgf0z/recursion-rec-4881-phase-3-design-aligned-with-fda-in-fap-drug-discovery-development</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n191o594/dignify-therapeutics-doses-first-healthy-participant-in-phase-1-study-of-dti-117-for-neuro</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nbptdno/pfizer-inks-cell-therapy-licensing-deal-with-starna-worth-up-to-2-6b-the-pharma-letter</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n18ny52d/pfizer-verismo-strike-licensing-deals-to-push-car-t-manufacturing-in-vivo-pharmaceutical-e</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n4ytcbw/stat-7-burning-questions-about-the-fda-s-post-overton-future</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nrapmes/merck-axes-2-7b-btk-inhibitor-program-after-seeing-phase-3-data</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n7mvtmv/biostream-receives-fda-breakthrough-device-designation-for-a-urine-test-to-aid-the-diagnos</loc>
    <lastmod>2026-11-18</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ndf1b4w/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1r02cim/hcltech-and-cohere-partner-to-build-and-deliver-sovereign-ai</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nfjqb/trackonomy-and-inve-technologies-partner-to-bring-physical-ai-to-enterprise-software-in-re</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nvq8xyf/victory-capital-stockholders-approve-stock-issuance-clearing-key-milestone-toward-first-ea</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n11gy14r/karyopharm-announces-fda-acceptance-of-supplemental-new-drug-application-for-xpovio-seline</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1t6ihu9/lilly-signs-5-9b-deal-with-stipple-to-unlock-oncology-targets</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/not2ugc/saturn-cloud-and-maiaedge-partner-to-expand-enterprise-access-to-secure-private-ai-inferen</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n143f5qe/zentist-and-asprodental-partner-to-advance-ai-powered-revenue-cycle-management-automation</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1hds9rw/cognito-reports-pivotal-phase-3-results-for-spectris-ad-a-non-invasive-at-home-approach-fo</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n14v978h/aribio-s-oral-alzheimer-s-drug-meets-primary-goal-in-monotherapy-arm-but-misses-in-full-po</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n183gah/emmes-selected-as-cro-partner-for-carra-registry-biorepository-supporting-the-next-generat</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nh8lspe/cloudkeeper-achieves-select-partner-tier-in-the-claude-partner-network-services-track</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1yq3o8m/alzheimer-s-pill-mirodenafil-meets-phase-3-goal-only-in-604-of-1-535-patients-not-on-stand</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nbhj345/rakuten-medical-initiates-first-in-human-phase-1-trial-of-pd-l1-targeted-rm-0256-photoimmu</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ncqazqg/acadia-pharmaceuticals-presents-additional-phase-2-radiant-study-quantisnow</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n9aag9l/aribio-s-oral-ar1001-meets-primary-efficacy-objective-in-prespecified-monotherapy-populati</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1t39e6o/perfuze-receives-fda-clearance-for-neurosheath-8f-long-sheath-completing-its-stroke-thromb</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nch9y7f/ionis-pharmaceuticals-ions-fda-approvals-pdufa-dates-drug-alerts-2026-ions-marketbeat</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ntvytmf/noah-wyle-and-figs-partner-together-to-relieve-at-least-200-million-of-medical-debt-nation</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nm1xn5o/vertex-signs-220m-deal-with-genomics-to-re-up-long-running-discovery-pact</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n117m7fu/medtronic-announces-fda-clearance-of-general-surgery-procedures-for-the-hugo-robotic-assis</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1fjw50u/sellas-launches-150m-stock-offering-after-phase-3-cancer-trial-win-dealroom</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1viq5q5/novartis-reports-positive-phase-3-data-on-ianalumab-for-sjogren-s-glance-by-eyes-on-eyecar</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nwpfqao/vy-spine-announces-fda-clearance-of-3d-printed-vysion-p-si-fusion-and-vystop-si-screw-syst</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nqjxwu/ensem-therapeutics-announces-dosing-of-first-patients-in-phase-1-2-clinical-trial-of-etx-9</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n13jnky5/karyopharm-announces-fda-acceptance-of-supplemental-new-drug-application-for-xpovio-seline</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1haz75q/fda-approves-bayer-s-blood-thinner-labroots</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nunkkib/sellas-life-sciences-announces-positive-pivotal-phase-3-regal-trial-data-showing-immunothe</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1591tsw/aribio-s-oral-alzheimer-s-drug-meets-monotherapy-goal-in-phase-3-as-fosun-weighs-licensing</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nzbcdxj/varsity-spirit-announces-zenni-optical-as-the-exclusive-eyewear-partner-of-varsity-spirit-</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1ba225u/aribio-s-alzheimer-s-drug-succeeds-in-phase-3-monotherapy</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1saxkcx/daewoong-pharma-reports-phase-1-autoimmune-drug-data-in-us-shows-over-90-target-occupancy</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1qi7xtr/onl-therapeutics-completes-enrollment-in-global-phase-2-galaxy-trial-of-xelafaslatide-in-p</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nqz8wqb/laboratoires-pierre-fabre-fda-fast-track-designation-for-elticertinib-in-nsclc</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1gur89c/sellas-life-sciences-reports-positive-phase-3-regal-trial-results-for-galinpepimut-s-in-am</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n2e4xbh/daewoong-pharmaceutical-presents-phase-1-clinical-trial-data-for-new-autoimmune-disease-dr</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1nr57uw/aribio-s-alzheimer-s-pill-slows-decline-31-in-patients-on-no-other-dementia-drugs-but-miss</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1645zee/maia-biotechnology-reports-consistent-strong-efficacy-in-expanded-phase-2-thio-101-study-i</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1fy62as/metavia-announces-completion-of-last-patient-visit-in-extended-24-week-phase-1-part-3a-stu</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1g0s7g0/rsna-2026-onpoint-surgical-s-fda-cleared-ar-spine-navigation-qualified-for-use-with-ge-hea</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nc03pq5/acadia-pharmaceuticals-presents-additional-phase-2-radiant-study-results-evaluating-remlif</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n91ns1g/rylo-and-raz-mobility-partner-to-expand-call-accessibility-for-seniors</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1m69s8a/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1jjl4c3/sellas-life-sciences-announces-positive-pivotal-phase-3-regal-trial-data-showing-immunothe</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1fnd8fm/karyopharm-announces-fda-acceptance-of-supplemental-new-drug-application-for-xpovio-seline</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1uamlv8/eikon-therapeutics-announces-clearance-to-proceed-with-first-in-human-phase-1-2-study-for-</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1i88d2/georgia-independent-athletic-association-partner-with-avive-to-bring-connected-aeds-to-mem</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ns3w5id/labcorp-to-expand-clinical-trial-operations-in-brazil-with-dedicated-kit-assembly-and-futu</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n2tda49/onl-therapeutics-completes-enrollment-in-global-phase-2-galaxy-trial-of-xelafaslatide-in-p</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1tjyfz4/harbour-biomed-s-partner-spruce-biosciences-separates-crhx-101-program-into-adrenyx-biosci</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nt29j81/astrazeneca-pharma-india-partners-with-strand-life-sciences-for-healthcare-collaboration-s</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nv489ty/aribio-confirms-ar1001-efficacy-in-phase-3-trial-raising-hopes-for-korea-s-first-oral-deme</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n139vyhy/vittoria-biotherapeutics-to-present-phase-1-results-for-senza5-cart5-in-t-cell-lymphoma-in</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nlx6ng6/radical-catheter-technologies-announces-fda-510-k-clearance-of-reperfusion-catheters-exten</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nhvqg83/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study-anvs-st</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nh1ijbu/gatc-health-and-hesperos-partner-to-build-fda-aligned-nams-workflow-that-aims-to-cut-time-</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1g8vpsk/ascletis-submits-ind-application-to-the-u-s-fda-for-asc36-37o-fdc-a-potentially-first-in-c</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n6vu07r/abbvie-abbv-taps-ai-drug-discovery-partnership-to-extend-its-research-pipeline-simply-wall</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n62de8c/stat-gop-maha-leaders-clash-over-fda-nominee-s-record-on-vapes</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1fn4hja/erasca-enters-into-clinical-collaboration-with-bristol-myers-squibb-to-evaluate-eras-0015-</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1hsjggl/maia-biotechnology-reports-consistent-strong-efficacy-in-expanded-phase-2-thio-101-study-i</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1th8aoo/annovis-receives-second-positive-dsmb-recommendation-for-its-phase-3-duet-ad-study</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1jumt06/edesa-biotech-granted-orphan-designation-for-paridiprubart-for-the-treatment-of-ards-by-th</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n7wvhzi/alsco-uniforms-named-official-partner-of-the-boston-celtics</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1j70ro1/karyopharm-announces-fda-acceptance-of-supplemental-new-drug-application-for-xpovio-seline</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n7appge/cognito-reports-pivotal-phase-3-results-for-spectris-ad-a-non-invasive-at-home-approach-fo</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n7gomkt/designing-a-pivotal-phase-3-cml-trial-around-physician-choice-and-patient-quality-of-life-</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nowrro3/biomolecular-life-holdings-inc-reaches-another-milestone-as-it-prepares-to-acquire-dr-daco</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n39etyd/daewoong-pharmaceutical-presents-phase-1-clinical-trial-data-for-new-autoimmune-disease-dr</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n7g37jw/gilead-grants-voluntary-licenses-of-experimental-ebola-drug-to-dr-reddy-s-two-others-pharm</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1sesnlb/cardio-diagnostics-to-unveil-non-obstructive-coronary-artery-disease-data-fda-breakthrough</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1gng6vg/ctad-alzheimer-s-pill-ar1001-misses-overall-mark-in-phase-3-slows-decline-only-in-one-subg</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ndo9o44/sellas-life-sciences-stock-sls-rockets-236-on-stellar-phase-3-trial-results-tipranks</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nrbtkpm/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1yg4aef/daewoong-pharmaceutical-presents-phase-1-clinical-trial-data-for-new-autoimmune-disease-dr</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1td9dho/sine-health-receives-fda-510-k-clearance-for-the-first-smartphone-essential-tremor-monitor</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n78ai1o/fda-s-complete-response-letter-for-summit-s-ivonescimab-cites-china-heavy-data-beyond-surv</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1bqt0a3/ichnos-glenmark-innovation-igi-announces-ind-submission-to-u-s-fda-for-isb-2301-a-first-in</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n11rjead/thyroscope-and-torc-announce-strategic-collaboration-to-advance-ai-driven-precision-medici</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ntmn97/mankind-pharma-licenses-ensartinib-for-indian-lung-cancer-market-voice-of-healthcare</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1xj80a/werfen-receives-us-fda-510-k-clearance-for-rotem-sigma-complete-cartridge-for-use-in-traum</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1h9evxk/simple-healthkit-partners-with-waters-corporation-to-bring-the-most-comprehensive-fda-clea</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nh3wosd/taylor-sheridan-s-bosque-ranch-names-lucy-first-nicotine-partner</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ncxcwxo/pulmatrix-announces-third-quarter-2026-financial-results-and-progress-on-merger</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1jtxvit/inflexion-s-rosemont-pharmaceuticals-to-acquire-aytu-biopharma-in-take-private-deal-pei-pr</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/niciaq3/thermosome-closes-global-licensing-agreement-with-avenor-the-pharma-letter</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1kbqd8s/daewoong-pharmaceutical-presents-phase-1-clinical-trial-data-for-new-autoimmune-disease-dr</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ndc1p13/aribio-s-alzheimer-s-drug-meets-phase-3-endpoint-in-subgroup-misses-in-overall-population-</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nxhrmsq/roche-breast-cancer-pill-cleared-by-fda</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ndavh09/labcorp-to-expand-clinical-trial-operations-in-brazil-with-dedicated-kit-assembly-and-futu</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1nxidyw/cancer-research-uk-and-dewpoint-therapeutics-partner-to-advance-potential-first-in-class-m</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nvje06j/metavia-announces-completion-of-last-patient-visit-in-extended-24-week-phase-1-part-3a-stu</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n6w47kp/eikon-therapeutics-announces-clearance-to-proceed-with-first-in-human-phase-1-2-study-for-</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n26tgyi/roche-enters-the-serd-market-with-fda-approval-in-late-stage-breast-cancer</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1mb5yt4/cytomx-therapeutics-announces-milestone-achievement-in-strategic-collaboration-with-regene</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1na9o2m/biomolecular-life-holdings-inc-reaches-another-milestone-as-it-prepares-to-acquire-dr-daco</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nm26jxq/cognition-therapeutics-announces-ctad-poster-highlighting-screening-efficiencies-with-p-ta</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ntheit9/gilead-grants-voluntary-licenses-of-experimental-ebola-drug-to-dr-reddy-s-two-others-pharm</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nro3elq/nordvpn-selects-havas-edge-as-u-s-agency-partner</loc>
    <lastmod>2026-11-17</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n37ldjs/lantheus-reports-positive-phase-3-results-for-tauklarify-pet-imaging-in-alzheimer-s-diseas</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1xwbqx/ice-and-abra-partner-to-bring-qualified-custody-to-institutional-digital-asset-loans-and-i</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1o81rr/quantum-x-and-everest-cloud-partner-to-bring-quantum-and-ai-compute-to-six-south-asian-mar</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1xme7hs/fuze-health-advances-chronic-care-through-its-technology-led-intelligent-care-platform-and</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1un9vsl/allarity-therapeutics-expands-phase-2-stenoparib-trial-to-three-ovarian-cancer-patient-coh</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n4gmurt/cg-oncology-s-bladder-cancer-therapy-cuts-recurrence-risk-68-in-phase-3-setting-up-two-fda</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nd8f0qr/sirtex-medical-announces-acquisition-of-the-fda-cleared-hourglass-vascular-plug</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nkdbc18/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1i2m32q/nuvation-bio-presented-additional-long-term-follow-up-data-from-phase-2-study-of-safusiden</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n8j7wy0/pivot-006-phase-3-registrational-trial-demonstrates-howl-link</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nlzusnp/hlb-therapeutics-rgn-259-fails-u-s-phase-3-trial-marking-sixth-straight-late-stage-setback</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1l0gbgu/biolinerx-and-hemispherian-present-phase-1-2a-clinical-study-and-pre-clinical-updates-incl</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1r3bj12/snappt-and-funnel-partner-to-bring-best-in-class-fraud-detection-and-income-verification-i</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nfaaesq/astrazeneca-secures-fda-approval-for-imfinzi-combo-in-mibc-pharmaceutical-technology</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nek3nn2/taiwan-s-obi-pharma-signs-collaboration-and-license-agreement-worth-2-b-with-novartis-bios</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n60tx7i/nuvation-bio-presented-additional-long-term-follow-up-data-from-phase-2-study-of-safusiden</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1cvxwvw/wiley-and-abridge-partner-to-bring-the-evidence-that-informs-clinical-guidelines-worldwide</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ns5p1n9/world-team-tennis-names-kallmeyer-as-exclusive-apparel-partner-and-official-outfitter</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1l3x8s2/roche-receives-fda-de-novo-authorization-for-cobas-pro-i-601-platform-with-ionify-gabapent</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nqn1pc4/biolinerx-and-hemispherian-present-phase-1-2a-clinical-study-and-pre-clinical-updates-incl</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/npvjbtc/sas-and-posit-partner-for-governed-ai-in-life-sciences</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nxuv6ia/fortvita-receives-its-first-positive-chmp-opinion-recommending-zybrivo-sintilimab-for-firs</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nutmknq/cue-biopharma-reports-positive-cue-221-phase-2-csu-results-and-initiates-first-in-human-do</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n15ht566/biolinerx-and-hemispherian-present-phase-1-2a-clinical-study-and-pre-clinical-updates-incl</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n12n2yeb/cg-oncology-announces-positive-phase-3-pivot-006-topline-results-for-cretostimogene-in-int</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n74w7b0/ori-biotech-strengthens-supply-chain-resilience-with-europlaz-alliance-business-weekly</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nam88ot/the-fda-and-psychedelics-what-s-been-happening-and-what-s-changed-healthcare-brew</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n19pdm91/helus-pharma-reports-positive-phase-3-hlp003-results-in-depression-study-tipranks</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nqtk85u/humacyte-presents-long-term-clinical-data-demonstrating-low-atherosclerosis-susceptibility</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nal2bw9/helus-pharma-announces-positive-topline-results-from-phase-3-approach-study-evaluating-hlp</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nzmgi8b/pivot-006-phase-3-registrational-trial-demonstrates-unprecedented-improvement-in-recurrenc</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ngimjc2/obi-pharma-signs-collaboration-and-license-agreement-with-novartis-corsicana-daily-sun</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nma7ckj/nervgen-advances-phase-3-trial-for-spinal-cord-injury-drug-nvg-291-with-fda-breakthrough-t</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1x8nf03/sas-and-posit-partner-for-governed-ai-in-life-sciences</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1d8otea/summit-shares-fall-as-fda-rejects-closely-watched-pd-1-vegf-drug</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ng8gln6/ideaya-biosciences-announces-successful-us-fda-type-c-meeting-on-phase-2-3-registrational-</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1hvfx9e/from-hong-kong-to-dusseldorf-hkstp-makes-medica-debut-with-breakthrough-medtech-ventures</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1k3xgjc/medicept-founder-f-david-rothkopf-to-show-medtech-teams-what-an-fda-inspection-looks-like-</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1ftnja4/medicept-founder-f-david-rothkopf-to-show-medtech-teams-what-an-fda-inspection-looks-like-</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n12jccrd/orphalan-expands-global-phase-3-traditional-study-in-wilson-disease-to-china-marking-first</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n6lxezd/povofortay-povorcitinib-approved-in-europe-as-the-first-once-daily-oral-treatment-for-adul</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nwwze42/cadillac-formula-1-team-welcomes-viatris-as-official-global-pharmaceutical-partner</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1hr4muy/biotech-s-monday-split-two-trial-wins-one-trial-miss-and-an-fda-rejection-quantisnow</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ndnq7hj/klygefa-gefurulimab-approved-in-the-us-for-the-treatment-of-generalised-myasthenia-gravis-</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1rf40sk/quralis-receives-fda-clearance-for-ind-application-of-qrl-201-for-the-treatment-of-als-cle</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1vs3x1z/rejuvenate-biomed-completes-last-patient-visit-in-phase-2-trial-of-rjx-01-in-copd-related-</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n19kuhn0/mankind-pharma-enters-into-in-licensing-agreement-with-betta-pharmaceuticals-for-an-exclus</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ncvueks/amylyx-pharmaceuticals-presents-results-from-phase-3-lucidity-clinical-trial-of-avexitide-</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nexpnio/arcturus-therapeutics-announces-50-million-investment-by-meiji-seika-pharma-as-part-of-exp</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n5yhk9b/helus-pharma-s-stock-slides-despite-successful-phase-3-depression-data</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nzoy5fs/helus-pharma-announces-positive-topline-results-from-phase-3-approach-study-evaluating-hlp</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nocrb2e/corxel-us-presents-full-phase-2-results-for-cx11-in-adults-with-overweight-and-obesity-at-</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nje3edv/biocon-gets-u-s-fda-approval-for-pebrilzo-pertuzumab-qcay-injection-a-biosimilar-to-perjet</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n15t2ojc/humacyte-presents-long-term-clinical-data-demonstrating-low-atherosclerosis-susceptibility</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1jnjvkj/precision-neuroscience-and-team-gleason-partner-to-give-the-als-community-a-voice-in-brain</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nde47qt/recon-fda-rejects-ivonescimab-for-lung-cancer-indication-j-j-to-buy-eye-disease-biotech-ol</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ngatvoo/mankind-licenses-lung-cancer-drug-ensartinib-from-china-s-betta-pharmaceuticals-pharma-eco</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nwv6hub/stat-fda-approves-new-breast-cancer-drug-providing-new-option-for-some-patients-boost-for-</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nkb08da/stat-in-a-win-for-maha-fda-creates-new-regulatory-category-for-the-supplement-nac</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nt4yobk/go2-for-lung-cancer-and-patient-data-vault-partner-to-expand-clinical-trial-navigation-acc</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1eaxstl/fda-approves-genentech-s-wilserdly-giredestrant-a-next-generation-oral-serd-for-er-positiv</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/new0is0/faeth-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ngqc6n3/three-fda-decisions-loom-after-summit-s-rejection-capricor-savara-alzheimer-s-data-top-bio</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nmkavh1/lexeo-therapeutics-announces-positive-interim-phase-i-ii-data-and-regulatory-update-for-lx</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nhegt0d/rein-therapeutics-announces-preliminary-blinded-phase-2-renew-data-showing-encouraging-lun</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1eactnq/biotech-s-monday-split-two-trial-wins-one-trial-miss-and-an-fda-rejection</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nztplpo/moleculin-biotech-posts-q3-loss-aml-trial-nears-data-readout-streetinsider</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1402xua/mankind-pharma-licenses-ensartinib-lung-cancer-drug-from-betta-rediff-moneywiz</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1q1kwzp/cognito-s-non-invasive-at-home-therapy-spectris-showed-consistent-slowing-of-cognitive-and</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nnkqppb/noema-pharma-receives-fda-orphan-drug-designation-for-basimglurant-for-the-treatment-of-tr</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nyui33d/cmb-and-verve-partner-to-put-customer-understanding-at-the-center-of-business-decisions</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n4g1mrm/aribio-s-oral-alzheimer-s-drug-shows-partial-effect-in-phase-3-seoul-economic-daily</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1hi6dky/lantheus-reports-phase-3-trial-results-for-alzheimer-s-tau-imaging-agent-investing-com-can</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1dyqx9l/mankind-pharma-enters-into-in-licensing-agreement-with-betta-pharmaceuticals-for-ensartini</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nkk8r59/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-th</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n9w7yvp/medavize-and-dateability-partner-to-empower-people-living-with-disabilities-and-chronic-co</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1i3a7iw/aribio-confirms-statistical-significance-for-oral-alzheimer-s-drug-in-phase-3-monotherapy-</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n2d5mhg/fortvita-receives-its-first-positive-chmp-opinion-recommending-zybrivo-sintilimab-for-firs</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nru9jee/helus-pharma-announces-positive-topline-results-from-phase-3-approach-study-evaluating-hlp</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1528y98/biotech-s-monday-split-two-trial-wins-one-trial-miss-and-an-fda-rejection</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ne8gk3s/ideaya-biosciences-announces-successful-us-fda-type-c-meeting-on-phase-2-3-registrational-</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1kyb28w/regnology-and-activeviam-partner-to-bring-the-same-granular-explainable-risk-intelligence-</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nceu85d/keypedia-and-fda-super-intelligence-terminology</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1yemg2b/helus-pharma-shares-fall-21-despite-phase-3-hlp003-trial-meeting-primary-endpoint</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1u1vecp/eli-lilly-to-acquire-biotech-firm-calytrix-bio-breakingthenews-net</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nxmjhfc/cardiff-oncology-receives-fda-fast-track-designation-for-onvansertib-in-first-line-ras-mut</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n11x42uf/cytokinetics-announces-prescribing-information-for-myqorzo-aficamten-expanded-to-include-d</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n190sbk6/trimtech-therapeutics-enters-strategic-research-collaboration-with-biogen-to-advance-small</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n30wabt/genentech-s-gazyva-becomes-the-first-fda-approved-treatment-for-primary-membranous-nephrop</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/naubn0z/helus-pharma-announces-positive-topline-results-from-phase</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n123rjzr/innovent-announces-positive-chmp-opinion-recommending-zybrivo-sintilimab-for-first-line-tr</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1pnc37/aribio-s-oral-dementia-drug-meets-primary-endpoint-in-global-phase-3-slows-progression-by-</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/naaz2g1/auxilius-joins-veeva-product-partner-program-to-deliver-a-clearer-view-of-clinical-trial-c</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nno1rj8/fda-doesn-t-approve-summit-s-china-developed-lung-cancer-drug-investor-s-business-daily</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1ca1skh/helus-pharma-help-reports-positive-phase-3-trial-results-for-major-depressive-disorder-adj</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nd1ekhl/nutrition-biotech-guide-shows-bulk-urolithin-a-powder-buyers-which-regulatory-record-appli</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ngpsbq9/spicy-organic-names-annatto-the-natural-answer-to-fda-s-synthetic-dye-phase-out</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/niws31v/sas-and-posit-partner-for-governed-ai-in-life-sciences</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1mwigqt/fda-rejects-cancer-drug-invented-in-china-in-blow-to-beijing-s-biotech-sector-financial-ti</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1deares/beren-therapeutics-announces-u-s-fda-approval-of-lembaz-adrabetadex-first-only-medicine-to</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nvmi3p8/lantheus-presents-data-from-two-pivotal-phase-3-studies-of-tauklarify-florquinitau-f-18-in</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n10427q1/helus-pharma-announces-positive-topline-results-from-phase-3-approach-study-evaluating-hlp</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n5g2jzz/cognito-reports-pivotal-phase-3-results-for-spectris-ad-a-non-invasive-at-home-approach-fo</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n82b25b/cytokinetics-wins-fda-approval-for-myqorzo-label-update-grafa-com</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1gh854/obi-pharma-signs-collaboration-and-license-agreement-with-novartis-via-tt</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ncw4koz/lucid-capital-raises-helus-pharma-help-price-target-to-79-after-positive-phase-3-trial-gur</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nr7buen/oculis-announces-fda-ind-clearance-enabling-acceleration-of-privosegtor-development-progra</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n15978d2/every-cure-and-openevidence-partner-to-repurpose-drugs-where-commercial-incentives-fall-sh</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nyuqz32/j-j-pays-2-2b-upfront-for-ollin-to-challenge-roche-s-vabysmo-with-phase-3-bispecific</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n17798n0/fortvita-receives-its-first-positive-chmp-opinion-recommending-zybrivo-sintilimab-for-firs</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nwkbumk/simplicity-group-acquires-dmi-marketing-adding-decades-of-advisor-relationships-and-annuit</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n15pvvn9/aclaris-therapeutics-announces-top-line-phase-2-results-for-its-anti-tslp-monoclonal-antib</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nhiano9/rein-therapeutics-announces-preliminary-blinded-phase-2-renew-data-showing-encouraging-lun</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1v870gp/cg-oncology-cgon-reports-positive-phase-3-trial-data-for-bladder-cancer-therapy-gurufocus</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1ajwp1k/jama-network-open-publishes-quality-of-life-and-pain-outcomes-data-from-phase-3-panova-3-t</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nl37w6f/biolinerx-and-hemispherian-present-phase-1-2a-clinical-study-and-pre-clinical-updates-incl</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1v0b4nn/cadillac-formula-1-team-welcomes-viatris-as-official-global-pharmaceutical-partner</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n10et462/biotech-etfs-brace-for-fda-showdown-two-drug-decisions-could-test-investor-sentiment-tradi</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1s2ybvp/obi-pharma-signs-a-collaboration-and-licensing-agreement-with-novartis-democrata</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n2nj1gk/cardiff-oncology-receives-fda-fast-track-designation-for-onvansertib-in-first-line-ras-mut</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1tw4i53/ideaya-biosciences-announces-successful-us-fda-type-c-meeting-on-phase-2-3-registrational-</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n91k5tw/rakuten-medical-initiates-first-in-human-phase-1-trial-of-pd-l1-targeted-rm-0256-photoimmu</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n10idw87/lilly-adds-to-buyout-streak-with-1-5b-purchase-of-startup-calytrix</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1djj7ks/ideaya-biosciences-announces-successful-us-fda-type-c-meeting-on-phase-2-3-registrational-</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nfwvx91/nuvation-bio-presented-additional-long-term-follow-up-data-from-phase-2-study-of-safusiden</loc>
    <lastmod>2026-11-16</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/napbjhq/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-a</loc>
    <lastmod>2026-11-15</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n12lbdus/fda-rejects-lung-cancer-treatment-ivonescimab-from-summit-therapeutics</loc>
    <lastmod>2026-11-15</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nqfvfwg/innovent-announces-positive-chmp-opinion-recommending-zybrivo-sintilimab-for-first-line-tr</loc>
    <lastmod>2026-11-15</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1009xrg/helus-pharma-to-present-phase-3-depression-trial-results-monday-by-investing-com-investing</loc>
    <lastmod>2026-11-15</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1y15got/helus-pharma-to-present-phase-3-depression-trial-results-monday-by-investing-com-investing</loc>
    <lastmod>2026-11-15</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n19vzqjz/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-a</loc>
    <lastmod>2026-11-15</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n115o46r/fda-rejects-summit-s-ivonescimab-derailing-us-arrival-of-much-hyped-pd-1xvegf-class-fierce</loc>
    <lastmod>2026-11-15</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n39haw4/helus-pharma-to-host-webcast-on-topline-phase-3-approach-study-results-for-hlp003-in-major</loc>
    <lastmod>2026-11-15</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nyg56tl/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-a</loc>
    <lastmod>2026-11-15</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nj3nsz1/helus-pharma-to-reveal-phase-3-trial-results-fo-pluang</loc>
    <lastmod>2026-11-15</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nvjg2ml/cagrisema-achieves-21-average-weight-loss-at-lower-doses-in-phase-3-trial-the-clinical-tri</loc>
    <lastmod>2026-11-15</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nb8kik2/helus-pharma-to-present-phase-3-depression-trial-results-monday-investing-com</loc>
    <lastmod>2026-11-15</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1rlkafv/stat-fda-rejects-lung-cancer-treatment-ivonescimab-from-summit-therapeutics</loc>
    <lastmod>2026-11-15</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1akig4k/regeneron-reports-positive-phase-2-results-for-baloncibart-in-pots-plans-phase-3-trial-voi</loc>
    <lastmod>2026-11-14</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nth5nk2/amylyx-pharmaceuticals-presents-results-from-phase-3-lucidity-clinical-trial-of-avexitide-</loc>
    <lastmod>2026-11-14</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n85kp6q/jade-biosciences-advances-jade101-phase-3-timeline-for-iga-nephropathy-the-clinical-trial-</loc>
    <lastmod>2026-11-14</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1r7dbct/servier-presents-updated-four-year-results-from-phase-2-firefly-1-study-of-ojemda-tovorafe</loc>
    <lastmod>2026-11-14</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1q3kh6p/rocket-pharma-s-rp-a501-danon-trial-gains-fda-alignment-on-endpoints-the-clinical-trial-va</loc>
    <lastmod>2026-11-14</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n10pxunf/amylyx-pharmaceuticals-presents-results-from-phase-3-lucidity-clinical-trial-of-avexitide-</loc>
    <lastmod>2026-11-14</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nwxiv4f/johnson-johnson-stock-caplyta-phase-3-study-meets-key-endpoints-ad-hoc-news-de</loc>
    <lastmod>2026-11-14</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nlvl9oz/ctad-2026-opens-monday-alzheimer-s-pill-ar1001-phase-3-data-due-amid-antibody-benefit-doub</loc>
    <lastmod>2026-11-14</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n15p9gmh/psychedelic-depression-drug-gh001-gets-initial-fda-feedback-lilly-owned-rival-advances-pha</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nldpog1/will-cancer-drug-partnership-change-sino-biopharmaceutical-s-sehk-1177-narrative-simply-wa</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1ok5zgq/cardiff-oncology-onvansertib-phase-2-data-shows-21-month-durability-in-mcrc-the-clinical-t</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1vqswuu/bracco-and-avicenna-ai-announce-fda-clearance-for-uptunity-aneurysm-a-new-ai-enabled-softw</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ndk7bnc/incyte-discontinues-planned-phase-3-ovarian-cancer-study-tipranks</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n33uin2/perioperative-imfinzi-approved-in-the-us-in-novel-regimen-with-neoadjuvant-enfortumab-vedo</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nc8xe4t/novartis-eyes-rhapsido-s-broader-use-on-positive-urticaria-data-drop</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1yfnu1r/tandem-mobi-now-fda-cleared-as-world-s-first-and-only-tubeless-aid-system-with-up-to-seven</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n3vtfhx/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1c328d8/fda-approval-for-lazcluze-issued-to-janssen-biotech-quantisnow</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ngoeyai/milestone-pharmaceuticals-reports-third-quarter-2026-financial-results-and-announces-cost-</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/np6zjz1/stat-oura-s-acquisition-of-health-tech-startup-raises-conflict-of-interest-questions-for-e</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1dgzg6f/jama-network-open-publishes-quality-of-life-and-pain-outcomes-data-from-phase-3-panova-3-t</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/njsarey/quantum-biopharma-achieve-91-increase-in-shareholder-equity-and-liquidity-in-q3-2026-as-lu</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ng08f0y/quantum-biopharma-achieve-91-increase-in-shareholder-equity-and-liquidity-in-q3-2026-as-lu</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nxhez7k/regeneron-posts-positive-phase-2-data-for-baloncibart-in-nervous-system-disorder-eyes-pivo</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1xun107/tennessee-oncology-and-protocol-partner-to-close-the-mental-health-gap-in-cancer-care</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n11ntsng/regeneron-posts-positive-phase-2-data-for-baloncibart-in-nervous-system-disorder-eyes-pivo</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1i1ys4e/silexion-therapeutics-reports-first-patient-dosed-in-phase-2-3-sil204-pancreatic-cancer-tr</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ntp0qs/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nfzuwob/prediction-10-000-invested-in-viking-therapeutics-before-its-oral-phase-3-readouts-could-b</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n138cnc/pozdeutinurad-achieves-sustained-serum-urate-reductions-in-phase-3-gout-trial-hospital-hea</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n5pi60j/priovant-announces-publication-of-phase-2-beacon-results-for-brepocitinib-in-cutaneous-sar</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1kyn6yv/eledon-tegoprubart-phase-3-kidney-transplant-trial-opens-as-cash-runway-extends-to-q2-2027</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n10gnxjz/aim-immunotech-approaches-major-clinical-inflection-point-with-phase-2-pancreatic-cancer-d</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1bcpbuh/organon-presents-new-analysis-of-pooled-post-hoc-phase-3-data-on-vtama-tapinarof-cream-1-d</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n3lrjxd/sls-stock-surges-after-hours-sellas-says-transformative-phase-3-aml-results-are-coming-thi</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/np0v8qz/overton-s-iffy-fda-confirmation-a-slashed-us-ipo-pharma-voice</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ndx8ssw/regeneron-s-pots-antibody-curbs-heart-rate-spikes-teeing-up-phase-3-trial-biospace</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1buh7on/rejoni-showcases-fda-approved-juveena-hydrogel-system-at-aagl-2026-global-congress-in-bost</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ncfyf3n/rezolute-reports-13-responders-in-preliminary-phase-3-tumor-study-mugglehead-investment-ma</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1kclex2/zealand-pharma-announces-eu-approval-of-zeydovio-glepaglutide-for-the-treatment-of-short-b</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n11txepg/johnson-johnson-stock-advances-as-prostate-drug-combo-enters-phase-3-ad-hoc-news-de</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1wdxmns/zayn-joins-focusfuel-as-investor-and-partner</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/ngar5y7/rezolute-reports-phase-3-uplift-study-meets-primary-efficacy-endpoint-in-tumor-hyperinsuli</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nw9pbmw/jama-network-open-publishes-quality-of-life-and-pain-outcomes-data-from-phase-3-panova-3-t</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n5rd2zm/virtuoso-surgical-nabs-fda-authorization-for-robotic-bladder-lesions-system</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nq9dspp/sellas-life-sciences-stock-jumps-20-after-hours-as-pivotal-leukemia-trial-results-near-big</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n10rfoc5/prediction-10-000-invested-in-viking-therapeutics-before-its-oral-phase-3-readouts-could-b</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1ser6l4/early-achieve-findings-move-z-basivarsen-toward-phase-3-in-myotonic-dystrophy-type-1-neuro</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n189q8mr/prediction-10-000-invested-in-viking-therapeutics-before-its-oral-phase-3-readouts-could-b</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nnddeth/bracco-and-avicenna-ai-announce-fda-clearance-for-uptunity-aneurysm-a-new-ai-enabled-softw</loc>
    <lastmod>2026-11-13</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nwb37s2/pharvaris-phvs-to-present-phase-3-trial-results-for-deucrictibant-xr-at-acaai-2026-gurufoc</loc>
    <lastmod>2026-11-12</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1jtelg5/neonc-technologies-holdings-announces-insider-buying-fda-meeting-for-neo100-and-upcoming-s</loc>
    <lastmod>2026-11-12</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1fllftu/pharvaris-reports-positive-phase-3-chapter-3-results-for-deucrictibant-xr-in-hereditary-an</loc>
    <lastmod>2026-11-12</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/nv535qe/hometown-soccer-holdings-selects-vivenu-as-its-ticketing-platform-partner</loc>
    <lastmod>2026-11-12</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1drlyrl/basata-and-unio-health-partners-partner-to-accelerate-patient-access-to-specialty-care</loc>
    <lastmod>2026-11-12</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n1m3psip/partner-daniel-p-o-toole-awarded-philanthropic-leadership-award-at-the-cristian-rivera-fou</loc>
    <lastmod>2026-11-12</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n7smh3x/abcellera-biologics-eyes-phase-3-for-hot-flash-drug-after-promising-midstage-results</loc>
    <lastmod>2026-11-12</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n9f9zmv/abbvie-abbv-reports-positive-phase-3-qulipta-migraine-trial-results</loc>
    <lastmod>2026-11-12</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
  <url>
    <loc>https://aktiv8.io/news/n11natyf/metavia-announces-statistically-significant-reduction-in-uric-acid-levels-with-da-1726-in-</loc>
    <lastmod>2026-11-12</lastmod>
    <changefreq>never</changefreq>
    <priority>0.6</priority>
  </url>
</urlset>